Patients with GLS > −16% did not significantly differ from patients with GLS < −16% regarding clinical data (patient age in years: 45.3 (9.9) vs. 42.6 (15.4), duration of illness in years: 32.5 (9.95) vs. 22.8 (13.9)), the extent of myocardial fibrosis (LGE in %: 1.1 (2.5) vs. 1.4 (1.8)), premature ventricular beats (PVB) per 24 h (57.5 (61) vs. 260.6 (1096)) and NT-proBNP in ρmol/L (4.3 (3.6) vs. 6.8 (10)) as well as all other examined cardiac biomarkers (i.e., CK, CKMB, hsTroponin T). The gene discussed is NPPB; the disease is Myocardial fibrosis.